Brain edema, also known as cerebral edema, occurs as a result of an increase in brain fluid content. Brain edema causes swelling of the brain due to excessive fluid collection in the chambers or ventricles of the brain or accumulation of fluid within the brain tissue itself. The causes of cerebral edema include traumatic brain injury, ischemic stroke, haemorrhages, tumors and infections (toxoplasmosis, meningitis, subdural empyema). Cerebral edema may or may not be associated with increased intracranial pressure. It may occur either due to cellular injury and swelling or disruption of the blood-brain barrier (vasogenic CE). Cerebral edema may arise in a variety of neurologic and non-neurologic illnesses.
Common non-neurological illnesses associated with cerebral edema include diabetic ketoacidosis, fulminant hepatic failure, ingestions and electrolyte abnormalities such as hyponatremia. Children with cerebral edema may be completely asymptomatic or exhibit varying degrees of symptoms specific to age. Children with cerebral edema require close monitoring and management, preferably in a pediatric intensive care unit. Some of the symptoms include headache, neck pain or stiffness, nausea or vomiting, dizziness, irregular breathing, vision loss or changes, memory loss, inability to walk, difficulty speaking, stupor, seizures and loss of consciousness. The drug candidates of brain edema pipeline include, but are not limited to, Glibenclamide, Cobitolimod and THR 18.
Some of the companies having drugs in the pipeline for brain edema include FibroGen, Inc., Pharmazz, Inc. and Remedy Pharmaceuticals, Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.